Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
There were some differences between pediatric rheumatologists and pediatric neurologist concerning the diagnostic testing rendered (chi square p < 0.05): Ig levels (pediatric rheumatologists 85% vs. pediatric neurologists 43%), anti-extractable nuclear antigen (ENA) antibodies (78% vs. 29%), capillary microscopy (70% vs. 14%), abdominal ultrasound (65% vs. 0%), serologic testing for infectious agents (42% vs. 0%) and childhood myositis assessment scale (CMAS) testing (83% vs. 0%), and, in contrast manual muscle testing (13% vs. 57%) and muscle biopsy (13% vs. 57%).Preferred testing in patients with probable juvenile dermatomyositisDiagnostic categoriesProportion of participants supporting testingSpecific diagnostic testsLaboratory diagnostics> 75% of participantsaErythrocyte sedimentation rate, GOT/AST, GPT/ALT, CK, LDH, ANA, CBC with differential count, CRP, BUN/creatinine, IgG/IgA/IgM50: 75% of participantsaC3 and C4, myositis blot, ENA panel, vWF antigen, total protein, ferritin, thyrotropin, uric acid, aldolase, rheumatoid factor and CCP antibody< 50% of participantsaAlbumin, 25-OH vitamin D, extended myositis blot (including anti-NXP2,: TIF1gamma, −MDA5), serologic testing for certain infections, cardiac-specific troponin, SPEP, NT pro-BNP, fecal calprotectin, serum neopterin, 1,25 (OH)2 vitamin D, tTG-IgA, lymphocyte subpopulations, stool occult bloodApparatus-based diagnostics or interventions> 75% of participantsaECG, pulmonary function testing, echocardiography, muscle MRI50: 75% of participantsamuscle ultrasound, nailfold capillaroscopy, abdominal ultrasound< 50% of participantsaChest radiograph, EMG, muscle biopsy, swallow study, chest CTJuvenile dermatomyositis-specific clinical scores or subspecialty consultations> 75% of participantsaN/A50: 75% of participantsaChildhood myositis assessment scale (CMAS)< 50% of participantsaDisease activity score, dermatology consultation, manual muscle testing (MMT)-8, neurology consultationAbbreviations: ANA antinuclear antibodies, ALT alanine aminotransferase, AST aspartate aminotransferase, BUN blood urea nitrogen, CBC complete blood count, CCP cyclic citrullinated peptide, CK creatine kinase, CRP C-reactive protein, ECG electrocardiogram, EMG electromyogram, ENA extractable nuclear antigen, GOT glutamate oxaloacetate transaminase, GPT glutamate pyruvate transaminase, Ig immunoglobulin, LDH lactate dehydrogenase, MRI magnetic resonance imaging, NT pro-BNP N-terminal pro-brain natriuretic peptide, SPEP serum protein electrophoresis, tTG tissue transglutaminase, vWF von Willebrand factoratests are listed in order of descending frequency
Source: Preferred diagnostic tools in patients with probable JDM. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists
Study design awaiting verification · Pediatric Rheumatology Online Journal · 2018
Original publication title
Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists
© The Author(s). 2018
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Juvenile Dermatomyositis (JDM) is a rare pediatric autoimmune disease with broad variations of the individual course. Data on the optimal management are mostly lacking. Currently treatment decisions are often based on experts’ opinions. In order to develop consensus-based treatment strategies for JDM in Germany a survey was pursued to analyze the current clinical practice.
Source: BackgroundAbstract: What methods does the paper describe?
An online survey addressing all members of the Society for Pediatric Rheumatology (GKJR) in Germany and Austria and pediatric neurologists with expertise in JDM was performed in February/March of 2016. The questionnaire consisted of 5 case scenarios including diagnostic criteria, treatment of moderate, severe and refractory JDM, using either multiple choice or a 5-point Likert scale. Basic descriptive statistics were used to analyze the findings.
Source: MethodsAbstract: Electronic supplementary material
The online version of this article (10.1186/s12969-018-0256-7) contains supplementary material, which is available to authorized users.
Source: Electronic supplementary materialAbstract: Results
The survey was completed by 60 pediatric rheumatologists and 7 pediatric neurologists experienced in the management of JDM. Typical findings allowing a diagnosis were considered to be: typical skin changes, proximal muscle weakness, MRI findings, elevated muscle enzymes, nailfold capillary changes, presence of calcinosis and muscle biopsy. Regarding induction treatment of moderate/severe JDM: 59%/74% opted for intermittent intravenous methylprednisolone (IVMP) pulse therapy, and 21%/40% for conventional high-dose oral glucocorticoids. Methotrexate (MTX) was the preferred disease-modifying conventional anti-rheumatic drug (cDMARD) for moderate and severe JDM.
Regarding the management of refractory moderate or severe JDM, intravenous immune globulins, mycophenolate mofetil and rituximab were preferred treatment options.
Source: ResultsAbstract: Conclusion
There is consensus about the diagnosis of JDM strongly supported by classic clinical and MRI findings. There is great variety in the treatment of JDM in Germany regarding both induction and maintenance therapy. The development of consensus-based treatment strategies for JDM based on harmonization of current clinical practice is essential in order to allow comparative effectiveness research in the future.
Source: ConclusionAuthors’ abstract
Background
Juvenile Dermatomyositis (JDM) is a rare pediatric autoimmune disease with broad variations of the individual course. Data on the optimal management are mostly lacking. Currently treatment decisions are often based on experts’ opinions. In order to develop consensus-based treatment strategies for JDM in Germany a survey was pursued to analyze the current clinical practice.
Methods
An online survey addressing all members of the Society for Pediatric Rheumatology (GKJR) in Germany and Austria and pediatric neurologists with expertise in JDM was performed in February/March of 2016. The questionnaire consisted of 5 case scenarios including diagnostic criteria, treatment of moderate, severe and refractory JDM, using either multiple choice or a 5-point Likert scale. Basic descriptive statistics were used to analyze the findings.
Results
The survey was completed by 60 pediatric rheumatologists and 7 pediatric neurologists experienced in the management of JDM. Typical findings allowing a diagnosis were considered to be: typical skin changes, proximal muscle weakness, MRI findings, elevated muscle enzymes, nailfold capillary changes, presence of calcinosis and muscle biopsy. Regarding induction treatment of moderate/severe JDM: 59%/74% opted for intermittent intravenous methylprednisolone (IVMP) pulse therapy, and 21%/40% for conventional high-dose oral glucocorticoids. Methotrexate (MTX) was the preferred disease-modifying conventional anti-rheumatic drug (cDMARD) for moderate and severe JDM.
Regarding the management of refractory moderate or severe JDM, intravenous immune globulins, mycophenolate mofetil and rituximab were preferred treatment options.
Conclusion
There is consensus about the diagnosis of JDM strongly supported by classic clinical and MRI findings. There is great variety in the treatment of JDM in Germany regarding both induction and maintenance therapy. The development of consensus-based treatment strategies for JDM based on harmonization of current clinical practice is essential in order to allow comparative effectiveness research in the future.
Electronic supplementary material
The online version of this article (10.1186/s12969-018-0256-7) contains supplementary material, which is available to authorized users.
Publication and source details
Original title: Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists
Claas H. Hinze; Fabian Speth; Prasad T. Oommen; Johannes-Peter Haas
Pediatric Rheumatology Online Journal · 2018
© The Author(s). 2018https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.Initiative für das rheumakranke KindNot applicableU can ride for arthritisNot applicableRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T19:06:10.891719+00:00
DOI: 10.1186/s12969-018-0256-7 · PMC6011340